Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported
EGFR is an important molecular target for drug treatment; however, the lack of relevant experimental models bearing non-canonical EGFR mutations (such as exon 20 insertions) has been a
The Phase 1 portion of the study will test the safety and tolerability of escalating doses of X4P-001 in combination with Inlyta (axitinib), a kinase inhibitor approved for
MGB Biopharma presented available Phase I and pre-clinical data together with a proposal for the further clinical development of oral MGB-BP-3 in Clostridium difficile infections (CDI). Following this
The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second
WAVE’s DMD program is based on preclinical data demonstrating an approximate 25-fold improvement in exon-skipping efficiency compared to drisapersen and eteplirsen, suggesting the potential for improved potency and
Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit
Hotung Group, and CDIB Capital Management, led the round with continued participation from existing investors, Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital
Stability studies demonstrated that, prior to mixing, ELIGARD may be stored at room temperature (59 – 86° F) for up to 8 weeks following removal from refrigeration. ELIGARD
The trial will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO, for the treatment of children with Attention Deficit Hyperactivity Disorder (ADHD). This large-scale
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.